LacdiNAc糖基化前列腺特异性抗原密度在预测磁共振-经直肠超声融合引导前列腺穿刺活检病理结果中的价值:针对PI-RADS分类≥3最高分患者的评估
本研究前瞻性纳入204例PSA 3.0–20 ng/mL且PI-RADS分类≥3的患者,评估LDN-PSA(LacdiNAc糖基化前列腺特异性抗原)检测临床显著前列腺癌的价值。多因素分析显示LDN-PSAD(OR 1.04,P=0.012)等为显著风险因素;在最高PI-RADS 3分的113例患者中,年龄(OR 1.10)和LDN-PSAD(OR 1.07,P<0.0001)为检测临床显著前列腺癌的风险因素。结论认为LDN-PSAD可作为生物标志物,其作为PSA的辅助手段可避免最高PI-RADS 3分患者的不必要活检,并建议开展多机构大样本研究。
要点
- LDN-PSAD与PSA密度、最高PI-RADS分类及病灶位置均为临床显著前列腺癌的显著风险因素。
- 在最高PI-RADS 3分患者中,年龄和LDN-PSAD是检测临床显著前列腺癌的风险因素。
- 作者认为LDN-PSAD作为PSA辅助手段可避免最高PI-RADS 3分患者的不必要活检,并建议多机构大样本研究。
核心结论
- LDN-PSAD可能成为PSA≤20 ng/mL且PI-RADS分类≥3可疑病灶患者检测临床显著前列腺癌的生物标志物。
- 作者认为LDN-PSAD作为PSA的辅助手段可避免最高PI-RADS 3分患者的不必要活检。
- 作者建议开展多机构大样本研究。
研究设计与样本
- 前瞻性纳入PSA 3.0–20 ng/mL且多参数磁共振疑似病灶PI-RADS分类≥3的患者。
- 共纳入204例患者,采用自动化两步Wisteria floribunda凝集素-抗PSA抗体夹心免疫分析法测定LDN-PSA。
主要发现
- 204例中检出临床显著前列腺癌105例。
- 多因素logistic回归分析显示,PSA密度(OR 1.61,P=0.010)、LDN-PSAD(OR 1.04,P=0.012)、最高PI-RADS分类(3 vs 4、5;OR 14.5,P<0.0001)及最高PI-RADS分类病灶位置(移行区 vs 外周带;OR 0.34,P=0.009)为检出临床显著前列腺癌的显著风险因素。
- 最高PI-RADS分类为3分的患者(n=113)中,检出临床显著前列腺癌28例。
- 在最高PI-RADS 3分患者中,预测检出临床显著前列腺癌的多因素logistic回归分析显示,年龄(OR 1.10,P=0.026)和LDN-PSAD(OR 1.07,P<0.0001)为风险因素。
临床怎么用
- 作者认为LDN-PSAD作为PSA的辅助手段可避免最高PI-RADS 3分患者的不必要活检。
- 作者建议开展多机构大样本研究。
局限性
- 作者建议开展多机构大样本研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the usefulness of the LDN-PSA (LacdiNAc-glycosylated-prostate specific antigen) in detecting clinically significant prostate cancer in patients suspected of having clinically significant prostate cancer on multiparametric magnetic resonance imaging. MATERIALS AND METHODS: Patients with prostate specific antigen levels ranging between 3.0 ng/mL and 20 ng/mL and suspicious lesions with PI-RADS (Prostate Imaging-Reporting and Data System) category ≥3 were included prospectively. The LDN-PSA was measured using an automated 2-step Wisteria floribunda agglutinin lectin-anti-prostate specific antigen antibody sandwich immunoassay. RESULTS: Two hundred four patients were included. Clinically significant prostate cancer was detected in 105 patients. On multivariable logistic regression analysis, prostate specific antigen density (OR 1.61, P = .010), LDN-PSAD (OR 1.04, P = .012), highest PI-RADS category (3 vs 4, 5; OR 14.5, P < .0001), and location of the lesion with highest PI-RADS category (transition zone vs peripheral zone) (OR 0.34, P = .009) were significant risk factors for detecting clinically significant prostate cancer. Among the patients with the highest PI-RADS category 3 (n=113), clinically significant prostate cancer was detected in 28 patients. On multivariable logistic regression analysis to predict the detection of clinically significant prostate cancer in patients with the highest PI-RADS category 3, age (OR 1.10, P = .026) and LDN-PSAD (OR 1.07, P < .0001) were risk factors for detecting clinically significant prostate cancer. CONCLUSIONS: LDN-PSAD would be a biomarker for detecting clinically significant prostate cancer in patients with prostate specific antigen levels ≤20 ng/mL and suspicious lesions with PI-RADS category ≥3. The use of LDN-PSAD as an adjunct to the use of prostate specific antigen levels would avoid unnecessary biopsies in patients with the highest PI-RADS category 3. Multi-institutional studies with large population are recommended.
引用
- Shoji S, Kaya T, Tanaka Y, et al. Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category ≥3. J Urol. 2022. PMID: 36067387. doi:10.1097/JU.0000000000002958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。